Fáddáevttohusat
Čájehuvvojit 1 - 20 oktiibuot 92 bohtosis ohcui ', ohcanáigi: 0,02s Aiddostahte ozu
  1. 1
    COVID-19 the anti-viral immune response /

    COVID-19 the anti-viral immune response /

    Almmustuhtton 2022
    Viečča ollesdeavstta
    Series
    Elektrovnnalaš Video
    Lasit oiddohiidda
    Furkejuvvon:
  2. 2
    International biobanking overview of key practices and policies /

    International biobanking overview of key practices and policies /

    Almmustuhtton 2022
    Viečča ollesdeavstta
    Series
    Elektrovnnalaš Video
    Lasit oiddohiidda
    Furkejuvvon:
  3. 3
    Biobanks and their role in biomedical research

    Biobanks and their role in biomedical research

    Almmustuhtton 2022
    Viečča ollesdeavstta
    Elektrovnnalaš Video
    Lasit oiddohiidda
    Furkejuvvon:
  4. 4
    Ethics and drug development

    Ethics and drug development

    Almmustuhtton 2022
    Viečča ollesdeavstta
    Elektrovnnalaš Video
    Lasit oiddohiidda
    Furkejuvvon:
  5. 5
    Tuberculosis and COVID-19

    Tuberculosis and COVID-19

    Almmustuhtton 2021
    Viečča ollesdeavstta
    Series
    Elektrovnnalaš Video
    Lasit oiddohiidda
    Furkejuvvon:
  6. 6
    SARS-CoV-2 monoclonal antibody testing in vivo

    SARS-CoV-2 monoclonal antibody testing in vivo

    Almmustuhtton 2021
    Viečča ollesdeavstta
    Series
    Elektrovnnalaš Jietna
    Lasit oiddohiidda
    Furkejuvvon:
  7. 7
    mRNA COVID-19 vaccine efficacy in recovered vs COVID-naive individuals

    mRNA COVID-19 vaccine efficacy in recovered vs COVID-naive individuals

    Almmustuhtton 2021
    Viečča ollesdeavstta
    Series
    Elektrovnnalaš Jietna
    Lasit oiddohiidda
    Furkejuvvon:
  8. 8
    SARS-CoV-2 variants implications for immunity and vaccine development /

    SARS-CoV-2 variants implications for immunity and vaccine development /

    Almmustuhtton 2021
    Viečča ollesdeavstta
    Series
    Elektrovnnalaš Jietna
    Lasit oiddohiidda
    Furkejuvvon:
  9. 9
    SARS-CoV-2 evolution emergence of the "Californian" and "Indian" variants /

    SARS-CoV-2 evolution emergence of the "Californian" and "Indian" variants /

    Almmustuhtton 2021
    Viečča ollesdeavstta
    Series
    Elektrovnnalaš Jietna
    Lasit oiddohiidda
    Furkejuvvon:
  10. 10
    SARS-COV-2 human monoclonal antibody therapy update

    SARS-COV-2 human monoclonal antibody therapy update

    Almmustuhtton 2021
    Viečča ollesdeavstta
    Series
    Elektrovnnalaš Jietna
    Lasit oiddohiidda
    Furkejuvvon:
  11. 11
    Emergence of blood clotting disorders resulting from COVID vaccines inoculations

    Emergence of blood clotting disorders resulting from COVID vaccines inoculations

    Almmustuhtton 2021
    Viečča ollesdeavstta
    Series
    Elektrovnnalaš Jietna
    Lasit oiddohiidda
    Furkejuvvon:
  12. 12
    SARS-CoV-2 evolution within and between individuals

    SARS-CoV-2 evolution within and between individuals

    Almmustuhtton 2021
    Viečča ollesdeavstta
    Series
    Elektrovnnalaš Jietna
    Lasit oiddohiidda
    Furkejuvvon:
  13. 13
    Identifying SARS-CoV-2 proteases

    Identifying SARS-CoV-2 proteases

    Almmustuhtton 2021
    Viečča ollesdeavstta
    Series
    Elektrovnnalaš Jietna
    Lasit oiddohiidda
    Furkejuvvon:
  14. 14
    Genetic surveillance and the emergence of SARS-CoV-2 variants

    Genetic surveillance and the emergence of SARS-CoV-2 variants

    Almmustuhtton 2021
    Viečča ollesdeavstta
    Series
    Elektrovnnalaš Jietna
    Lasit oiddohiidda
    Furkejuvvon:
  15. 15
    The immune system response to the SARS-CoV-2 virus March 2021 update /

    The immune system response to the SARS-CoV-2 virus March 2021 update /

    Almmustuhtton 2021
    Viečča ollesdeavstta
    Series
    Elektrovnnalaš Jietna
    Lasit oiddohiidda
    Furkejuvvon:
  16. 16
    ABO blood groups and SARS-CoV-2 susceptibility

    ABO blood groups and SARS-CoV-2 susceptibility

    Almmustuhtton 2021
    Viečča ollesdeavstta
    Series
    Elektrovnnalaš Jietna
    Lasit oiddohiidda
    Furkejuvvon:
  17. 17
    Comparison of COVID-19 and seasonal HCoV pathologies and transfer to endemic state

    Comparison of COVID-19 and seasonal HCoV pathologies and transfer to endemic state

    Almmustuhtton 2021
    Viečča ollesdeavstta
    Series
    Elektrovnnalaš Jietna
    Lasit oiddohiidda
    Furkejuvvon:
  18. 18
    The role of short linear motifs (SLiMs) in SARS-CoV-2 entry into human cells

    The role of short linear motifs (SLiMs) in SARS-CoV-2 entry into human cells

    Almmustuhtton 2021
    Viečča ollesdeavstta
    Series
    Elektrovnnalaš Jietna
    Lasit oiddohiidda
    Furkejuvvon:
  19. 19
    The role of Neuropilin-1 as a SARS-CoV-2-specific endocytosis potentiator

    The role of Neuropilin-1 as a SARS-CoV-2-specific endocytosis potentiator

    Almmustuhtton 2021
    Viečča ollesdeavstta
    Series
    Elektrovnnalaš Jietna
    Lasit oiddohiidda
    Furkejuvvon:
  20. 20
    COVID-19 epidemiology and variants new challenges and future of the pandemic /

    COVID-19 epidemiology and variants new challenges and future of the pandemic /

    Almmustuhtton 2021
    Viečča ollesdeavstta
    Series
    Elektrovnnalaš Jietna
    Lasit oiddohiidda
    Furkejuvvon:

Ohcanreaiddut: